India's Mankind Pharma posts lower quarterly profit as costs surge

Mankind Pharma

31/07/2025 13:24

July 31 (Reuters) - Indian drugmaker Mankind Pharma MNKI.NS reported a lower first-quarter profit on Thursday, as mounting expenses outpaced strong domestic demand, particularly for drugs treating long-term illnesses.

The company, which makes 'Gas-O-Fast' antacid tablets and 'Manforce' condoms, reported an 18% drop in its consolidated net profit to 4.38 billion rupees ($50 million) for the quarter ended June 30.

Overall revenue climbed 24.5% to 35.70 billion rupees, but was overshadowed by a 35% jump in total expenses, leading to a decline in profit.

For further earnings highlights, click nFWN3TS1NU.

KEY CONTEXT

The Indian pharmaceuticals market grew 6% during the quarter, led by a 10% growth in the chronic segment, according to IQVIA data.

This benefitted Mankind Pharma and its peer Torrent Pharma TORP.NS, which derive most of their sales from drugs that treat long-term conditions such as diabetes and hypertension.

Earlier this week, Torrent Pharma TORP.NS reported a higher June quarter profit, driven by demand for drugs used to treat long-term conditions.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Mankind Pharma Ltd
MNKI.NS
46.66
27.87
18.00
13.98
Buy
15
0.96
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
31.99
20.99
12.41
18.95
Buy
12
0.87
Torrent Pharmaceuticals Ltd
TORP.NS
46.35
27.76
12.48
25.42
Buy
29
0.99
Glenmark Pharmaceuticals Ltd
GLEN.NS
32.30
19.29
12.66
27.16
Buy
9
0.99

  * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
 ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

APRIL TO JUNE STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 87.5890 Indian rupees

Mankind Pharma's Q1 stock performance vs peers https://reut.rs/3TWIz4Z

 (Reporting by Kashish Tandon in Bengaluru; Editing by Sonia Cheema)

 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))